EVALUATING THE PRODUCTION STABILITY OF MEASLES VACCINE AND MEASLES – RUBELLA COMBINED VACCINE FROM 2015-2021 THROUGH QUALITY ASSESMENT OF ANNUAL REPRESENTATIVE VACCINE PRODUCED AT POLYVAC

Abstract

 For the purpose of evaluating the stability of manufacturing process through quality assessment of annual representative lot of vaccine produced at POLYVAC taken each year, measles vaccine and combined measles-rubella vaccine were sampling with a frequency of 1 lot/ year/ 1 type of vaccine from 2015 to 2021. Vaccine samples were stored at 2-8 ⁰C, be sampled periodically at 0 year, 1 year, 2 year point to check the quality according to potency; residual moisture; description and pH test. At the 2 year point particularly, vaccine lots produced from 2021 will be performed additional ECTC testing. The results were within the standard range at all tests and time points.